PHIO PHARMACEUTICALS CORP. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.8197 USD | +5.67% |
|
+20.19% | +7.86% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 6.296 | 15.55 | 13.53 | 5.084 | 1.857 | 3.764 |
| Enterprise Value (EV) 1 | 6.296 | 15.55 | 13.53 | 5.084 | 1.857 | 3.764 |
| P/E ratio | -0.49 x | -1.4 x | -0.96 x | -0.44 x | -0.15 x | -0.23 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 300 x | - | - | - | - | - |
| EV / Revenue | 300 x | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 55.8 | 482 | 1,128 | 1,139 | 2,443 | 4,592 |
| Reference price 2 | 112.9 | 32.28 | 12.00 | 4.464 | 0.7600 | 0.8197 |
| Announcement Date | 20-03-26 | 21-03-25 | 22-03-22 | 23-03-22 | 24-04-01 | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Net sales 1 | 0.021 | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | -8.987 | -8.793 | -13.51 | -11.46 | -10.82 | -13.4 |
| Operating Margin | -42,795.24% | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -8.908 | -8.794 | -13.29 | -11.48 | -10.83 | -13.4 |
| Net income 1 | -8.908 | -8.794 | -13.29 | -11.48 | -10.83 | -13.4 |
| Net margin | -42,419.05% | - | - | - | - | - |
| EPS 2 | -232.0 | -23.04 | -12.48 | -10.10 | -5.200 | -3.560 |
| Free Cash Flow | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 20-03-26 | 21-03-25 | 22-03-22 | 23-03-22 | 24-04-01 | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q2 | 2023 Q3 | 2023 Q4 |
|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -3.739 | -3.45 | -2.64 | -2.521 | -3.571 | -2.73 | - | -2.776 | -1.899 |
| Operating Margin | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -3.742 | -3.451 | -2.642 | -2.531 | -3.576 | -2.731 | - | -2.78 | -1.895 |
| Net income 1 | -3.742 | -3.451 | -2.642 | -2.531 | -3.576 | -2.731 | -2.549 | -2.78 | -1.895 |
| Net margin | - | - | - | - | - | - | - | - | - |
| EPS 2 | -3.360 | -3.120 | -2.280 | -2.280 | -3.120 | -2.420 | -1.470 | -1.140 | -0.1700 |
| Dividend per Share | - | - | - | - | - | - | - | - | - |
| Announcement Date | 21-11-10 | 22-03-22 | 22-05-12 | 22-08-11 | 22-11-10 | 23-03-22 | 23-08-10 | 23-11-09 | 24-04-01 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 20-03-26 | 21-03-25 | 22-03-22 | 23-03-22 | 24-04-01 | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.8197
USD
Average target price
4
USD
Spread / Average Target
+387.98%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +7.86% | 3.76M | |
| +25.69% | 47.86B | |
| +46.90% | 41.42B | |
| -3.46% | 40.66B | |
| -6.20% | 28.92B | |
| +9.17% | 25.55B | |
| -20.42% | 19.27B | |
| +0.17% | 12.15B | |
| +28.07% | 12.14B | |
| -1.24% | 11.99B |
- Stock Market
- Equities
- PHIO Stock
- Financials Phio Pharmaceuticals Corp.
